Slide 1: ViroGates A/S Investor Presentation
ViroGates ViroGates A/S Investor Presentation 16 June 2020 Danske Bank, Copenhagen
Slide 2: Forward-looking statements
ViroGates Forward-looking statements Certain information set forth and given in this presentation contains “forward-looking information”, including “future oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking st
Slide 3: ViroGates - a commercial stage company with approved products for the hospital sector
ViroGates 3 ViroGates - a commercial stage company with approved products for the hospital sector ViroGates suPARnostic® products suPAR is the biomarker detected by ViroGates’ three CE-IVD marked suPARnostic® products and is a protein found in plasma. Description ViroGates A/S is an international me
Slide 4: suPAR is a marker of immune activation and a strong predictor disease severity and progression
ViroGates 4 suPAR is a marker of immune activation and a strong predictor disease severity and progession suPAR (soluble urokinase Plasminogen Activator Receptor) uPAR DI DII suPAR DI DII suPARnostic® - +600 peer reviewed papers supporting A prognostic inflammatory DIII DIII evidence biomarker for i
Slide 5: Sales organization in place for a product with substantial clinical evidence and first customers
ViroGates 5 Sales organization in place for a product with substantial clinical evidence and first customers in place 8 hospitals with suPAR in clinical routine in 4 countries Commercial Focus We listed to achieve funds to develop a commercial Næstved Hosp. organization to market our products in sel
Slide 6: suPARnostic Value propositions
ViroGates 6 suPARnostic® Value propositions Indicative effects of using suPAR 34% Improve patient care more patients classified into low-risk, discharge category and with lower mortality1 6% reduction in hospital length-of-stay per patient2 Reduce healthcare costs €100-380 savings per admission depe
Slide 7: suPARnostic has an obvious role to play in Covid-19
ViroGates 7 suPARnostic® has an obvious role to play in Covid-19 suPAR as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia Rovina et al, Critical Care Journal, 2020 Key findings • suPAR may early trace COVID-19 patients who develop severe respiratory failure • Pat
Slide 8: The suPARnostic TurbiLatex product fits into routine blood work and has been validated
ViroGates 8 The suPARnostic® TurbiLatex product fits into routine blood work and has been validated on analyzers used in clinical biochemistry Easy to use Fits directly into existing work flow and turnaround time in clinical biochemistry with no additional samples or work flow steps needed Validated
Slide 9: Compared to standard triaging, suPARnostic reveals more low-risk patients and more high-risk patients
ViroGates 9 Compared to standard triaging, suPARnostic® reveals more low-risk patients and more high-risk patients Triage group No suPARnostic® suPAR-supported triaging Outcome Share of patients Share of patients Improved patient care and Personal reduced healthcare costs: walk in Low risk • More di
Slide 10: ViroGates has a global ~€1 billion market opportunity in Acute Care
ViroGates 10 ViroGates has a global ~€1 billion market opportunity in Acute Care – healthcare savings potential varies across markets Global ViroGates market opportunity in Acute Care Healthcare savings potential in Acute Care (example markets)* Million EUR Million EUR Net healthcare savings Cost of
Slide 11: ViroGates has significant future opportunities beyond Acute Care
ViroGates 11 ViroGates has significant future opportunities beyond Acute Care General Practitioners Private Health Tests ~19 billion EUR market opportunity ~27 billion EUR market opportunity • Health screens and regular visits at • Private Health tests are conducted at the GP offices independent lab
Slide 12: The current focus is on commercialization – most of the proceeds from the IPO
ViroGates The current focus is on commercialization – most of the proceeds from the IPO is dedicated to boosting commercial execution Status and outlook Use of proceeds Clinical IP Prepare documentation 0.4 • Ensure adequate product offering 1 • Validate the product clinically 1.0 • Perform health e
Slide 13: ViroGates has an experienced management team and board
ViroGates 13 ViroGates has an experienced management team and board Management Team Non-Executive Board Jakob Knudsen, CEO, LL.M & MBA Dr. Lars Kongsbak (Chairman) • +15 years operational experience in life science • +25 years operational experience in • CEO ViroGates A/S since 2011, CCO and CFO Ega
Slide 14: A Danish region serving seven hospitals became a clinical customer
ViroGates 14 A Danish region serving seven hospitals became a clinical customer - TurbiLatex is now validated on ADVIA® XPT Business highlights in Q1, 2020 • Announced clinical implementation of suPARnostic® Quick Triage at hospitals in Region Zealand and to be conducted by the clinical immunology d
Slide 15: Thank you for your attention!
ViroGates 15 Thank you for your attention! Jakob Knudsen +45 2226 1355 jk@virogates.com